Immuneering (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 2,298 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall purchased 2,298 shares of the stock in a transaction on Thursday, January 15th. The stock was acquired at an average cost of $4.57 per share, for a total transaction of $10,501.86. Following the acquisition, the insider owned 376,496 shares in the company, valued at approximately $1,720,586.72. This represents a 0.61% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Immuneering Trading Down 1.3%

Shares of NASDAQ IMRX opened at $4.58 on Friday. The business has a 50-day moving average of $6.37 and a 200-day moving average of $5.78. The firm has a market capitalization of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering Corporation has a 12 month low of $1.10 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, analysts predict that Immuneering Corporation will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Hedge funds and other institutional investors have recently modified their holdings of the stock. Iridian Asset Management LLC CT purchased a new stake in Immuneering in the third quarter worth about $1,926,000. Flower City Capital purchased a new position in shares of Immuneering during the 2nd quarter worth approximately $108,000. Kingsview Wealth Management LLC bought a new position in shares of Immuneering in the 2nd quarter worth approximately $47,000. GSA Capital Partners LLP purchased a new position in shares of Immuneering in the 3rd quarter valued at approximately $265,000. Finally, Palumbo Wealth Management LLC bought a new stake in shares of Immuneering during the third quarter valued at approximately $343,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IMRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Leerink Partnrs upgraded shares of Immuneering to a “strong-buy” rating in a report on Friday, October 31st. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Oppenheimer boosted their price objective on shares of Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Immuneering in a report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.